Anzeige
Mehr »
Login
Freitag, 18.04.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Trumps Dekret beschleunigt Antimon-Boom - Wird Global Tactical der nächste Highflyer für kritische Mineralien?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QB6B | ISIN: US26818M1080 | Ticker-Symbol:
NASDAQ
17.04.25
21:59 Uhr
8,165 US-Dollar
0,000
0,00 %
1-Jahres-Chart
DYNE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
DYNE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur DYNE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiDyne Therapeutics, Inc.: Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments86- Vikram Ranade, PhD, appointed as chief business officer - - Ranjan Batra, PhD, appointed as chief scientific officer - - Oxana Beskrovnaya, PhD, transitioning to chief innovation officer - WALTHAM...
► Artikel lesen
MoDyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)43WALTHAM, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically...
► Artikel lesen
DYNE THERAPEUTICS Aktie jetzt für 0€ handeln
27.03.Dyne Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
26.03.BMO maintains Dyne Therapeutics stock with $50 target1
21.03.JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path2
21.03.AstraZeneca deepens China investment; Editas loses CFO to Dyne13
20.03.JPMorgan cuts Dyne Therapeutics stock target to $17 from $183
20.03.Dyne Therapeutics Names Erick Lucera As CFO352WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases...
► Artikel lesen
20.03.Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer230WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically...
► Artikel lesen
20.03.Dyne Therapeutics ernennt neuen CFO vor wichtigen klinischen Meilensteinen6
20.03.Dyne Therapeutics names new CFO ahead of clinical milestones3
20.03.Dyne Therapeutics appoints Erick Lucera as CFO2
20.03.Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer137- Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation - WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics...
► Artikel lesen
20.03.Dyne Therapeutics, Inc. - 8-K, Current Report2
17.03.H.C. Wainwright maintains $46 target on Dyne Therapeutics stock1
17.03.Piper Sandler maintains overweight on Dyne stock with $48 target2
17.03.Stifel maintains Buy on Dyne Therapeutics with $66 target2
17.03.Chardan keeps Dyne Therapeutics stock Buy rating, $50 target1
17.03.Dyne reports new long-term data from Phase 1/2 DELIVER trial of DYNE-2511
17.03.Dyne: Phase 1/2 Trial Of DYNE-251 In DMD Shows Sustained Functional Improvements Through 18 Months407WASHINGTON (dpa-AFX) - Dyne Therapeutics Inc. (DYN) announced new long-term clinical data from its Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented and sustained functional improvement...
► Artikel lesen
Seite:  Weiter >>
65 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1